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Abstract
Background. The aim of this randomised prospective study was to evaluate hepatic encephalopathy after mesocaval inter-
position shunt operation and after repeated endoscopic sclerotherapy. Methods. Forty-five patients with bleeding oesophageal
varices due to liver cirrhosis were randomised to the two treatment groups, 24 to the shunt group and 21 to the sclerotherapy
group. The patients were evaluated preoperatively regarding blood tests, hepatic encephalopathy as measured by electro-
encephalogram with spectral analysis and by a battery of psychometric tests. The direction of portal flow in the shunt group
was investigated by shunt phlebography and ultrasonography with Doppler. During follow-up the same investigations were
performed twice at median 6.7 and 14.7 months after operation. Results. No statistically significant difference was found
during follow-up regarding blood tests and electroencephalography with spectral analysis. Although the preoperative
psychometric tests showed that the shunt group performed significantly better than the sclerotherapy group, the first follow-up
showed that the shunt group performed statistically worse than the sclerotherapy group in seven of the tests: Synonyms
(measuring verbal ability), Block Design Test (measuring visuo-spatial ability), Memory for Design Test, Error Score
(measuring memory function), Revised Visual Retention Test, correct answers and the same test error answers (measuring
visuo-spatial memory, ability and immediate memory), Digit Symbol Test (measuring perceptual ability) and Trial Making
Test B (measuring cognitive motor abilities). Conclusions. Patients treated by mesocaval interposition shunt showed a
progressive general reduction in psychometric performance compared with patients treated with repeated sclerotherapy, in
whom a general intellectual improvement was observed. This finding corresponds to the reverse direction of the preoperative
portal flow to a hepatofugal pattern at first follow-up and at 12 months among two-thirds of the patients.
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Introduction
All treatments of bleeding oesophageal varices other
than liver transplantation aim to control the symptoms
arising from the persistent underlying hepatic disorder.
Generally these varices are associated with an alcohol-
induced cirrhosis of the liver. Besides life-threatening
gastrointestinal bleeding, the hepatic encephalopathy
(HE) that frequently occurs in this situation is a major
clinical problem both in the short term and the long
term.
Oesophageal varices are usually treated either by
endoscopic sclerotherapy or by portosystemic shunting
of blood. The influence of these therapies on the
development of HE has not been adequately scruti-
nised. Results from several studies display considerable
differences; the reason may be differences in treatment
modalities as well as in evaluation techniques. Various
degrees of HE have been reported to appear in 16–77%
of patients after shunt surgery and in 7–12% after
sclerotherapy [1–4]. In a meta-analysis of comparisons
of a selective shunt, the distal spleno-renal shunt
(DSRS) and sclerotherapy, it was concluded that the
overall risk for development of chronic HE was slightly
increased after DSRS in non-alcoholic patients, while
there was no increased risk after DSRS in the studied
groups as a whole [5]. A new shunt procedure has been
introduced in recent years, the transjugular intra-
hepatic portasystemic shunt (TIPS). The incidence of
HE arising as a result of the TIPS procedure is be-
tween 15 and 25% [6], a higher incidence than after
sclerotherapy [7].
We initiated this study to investigate whether or
not portosystemic shunting would result in more
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pronounced HE than sclerotherapy; mesocaval in-
terposition shunt (MIS) was used as the surgical
alternative to endoscopic sclerotherapy (ST). This
procedure acts as a complete shunt, because with time
it totally siphons off the portal venous perfusion [8]. In
an earlier report [9] of a prospective randomised trial
comparing MIS and repeated ST as regards rebleeding
and encephalopathy, we found no differences between
the incidence of HE within 3 years of MIS. In that
study we analysed the total scores of all psychometric
tests in the two treatment groups. Using a more
sophisticated method to analyse the data from the
psychometric test results, which is described in the
present study, we found several important changes in
the development of HE between the shunt and the
sclerotherapy group.
Materials and methods
Patients
This study, which started in January 1980 and closed
in December 1989, was carried out at the Surgical
Department, University Hospital, Lund. Informed
consent was obtained from each patient and the study
was approved by the ethical committee for human
studies at Lund University.
The patients all had bleeding oesophageal varices
due to liver cirrhosis, histologically verified by pre-
operative thick-needle biopsy, and portal hyper-
tension. The criteria for inclusion in the study were (1)
age between 20 and 75 years, (2) the bleeding source
should be oesophageal varices verified endoscopically,
(3) presence of portal hypertension, (4) the diagnosis of
liver cirrhosis as proven histologically.
After emergency treatment of the bleeding varices
with sclerotherapy, the patients were randomised into
two elective treatment groups. Randomisation to the
two treatment groups was done for patients fulfilling
the inclusion criteria after they had been stratified
according to Child’s class. The randomisation was
done by using closed envelopes. The results of the
psychometric tests and EEG were not included in
the randomisation procedure. Forty-five patients were
included in the study, comprising 32 men and 13
women with a median age of 54 years (range 31–68).
Twenty-four patients (19 men and 5 women) were
randomised to mesocaval interposition shunt and 21
patients (13 men and 8 women) to sclerotherapy.
During the same period, 180 other patients with
bleeding oesophageal varices were treated with re-
peated ST, 36 were treated by MIS and 15 with a
portacaval shunt.
All Child’s classes were represented: 15% of patients
belonged to Child’s class A, 56% to Child’s B and 29%
to Child’s C. As earlier studies on shunting procedures
have not given conclusive results regarding outcome
in Child’s C patients compared to B patients, there
seemed no reason to exclude Child’s class C patients.
No statistical differences in the distribution of age, sex,
albumin levels or Child’s classification could be found
between the two groups. Fourteen patients (67%) in
the sclerotherapy group and 19 patients (81%) in the
shunt group had a history of alcohol abuse.
Methods
Mesocaval interposition shunt was created by place-
ment of a 14-mm PTFE, polytetrafluoroethylene graft
(Gore-Tex1, WL Gore & Associates Inc. Medical
Products, Flagstaff, AZ, USA) between the superior
mesenteric vein and the inferior vena cava. Sclero-
therapy was performed at flexible endoscopy with
repeated injections of polidocanol 10 mg/ml (Aetho-
xysclerol1, Chemische Fabrik Kreussler & Co.,
GmbH, D-6200, Wiesbaden-Biebrick, Germany) both
submucosally and paravariceally until the varices were
eradicated.
All patients in the study underwent evaluation of
cerebral activity by EEG with spectral analysis and with
12 different psychometric tests before randomisation
to either of the two treatment groups.
Following a decision by the ethical committee, the
patients in the ST group were not investigated with
invasive radiological techniques to study portal flow.
Thus the portal flow was only investigated in the MIS
group. Portal flow was examined preoperatively by the
use of conventional angiography and during follow-
up by shunt phlebography, later (1984) replaced by
ultrasonography [10]. The latter technique was first
performed with Diasonic DRF 12 equipment, later
with a Toshiba 90 and after 1986 with a Toshiba 100
Doppler Duplex.
The preoperative work-up procedure also included
a routine blood chemistry screening. The same
blood tests were monitored in all controls during
follow-up. The following blood tests were analysed:
haemoglobin (g/l), platelet count (109/l), activated
thromboplastin time (APTT), normotest (NT), a liver
failure test sensitive to small reductions of vitamin K,
bilirubin (mmol/l), alkaline phosphatase (ALP; mkat/l),
glutamyltransferase (GT; mkat/l), aspartate-amino-
transferase (ALAT; mkat/l), creatinine (mkat/l),
amylase (mkat/l), albumin (g/l) and urea (mmol/l). The
tests were analysed according to the routine methods
used in the Department of Clinical Chemistry, Lund
University Hospital, Lund.
EEG
EEG was recorded with a 16-channel Siemens-Elema
electroencephalograph (time constant 0.3 s, low pass
filter 70 Hz). Quantitative frequency analysis was
made from four bipolar channels symmetrically placed
over precentral and parietal areas denoted as (F3-C3;
C3-P3; F4-C4; C4-P4) using a Fast Fourier Trans-
form (FFT) algorithm (Brain-Lab program, Digital on
a PDP 11/03 computer). An average FFT spectrum
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from a total 10 min of EEG recording was calculated
(sampling frequency 240 Hz). The EEG power within
the delta and theta ranges (=0.5–8 Hz) from all
four channels divided by the total power (0.5–25 Hz)
was used as an index of EEG pathology (LFP, low
frequency power ratio). The higher the value of the
LFP ratio, the more severe the HE [11,12]. The results
of the EEG measures are expressed as LFP ratio scores.
To calculate the median value for normal persons, a
control group (n=26) was randomly selected from the
population register among subjects without a history of
cerebral disorder. Neurological examination of these
subjects did not reveal any signs of CNS abnormality
or any evidence of alcoholism. The control group
consisted of 12 women and 14 men, median age 61
years (SD 47). There was no statistically significant
difference between the control group and the two
treatment groups according to age. The median LFP
ratio of the control group was 41, SD 53.
Psychometric tests
The psychometric tests used to evaluate cognitive
functions are listed in Table I [13–23]. The results of
the psychometric tests are all expressed in raw scores,
i.e. the values obtained from the original recordings.
The control group for psychometric testing con-
sisted of 22 healthy male industrial workers with no
evidence of alcoholism. The median age of the control
group was 62 years (range 36–67). There was no
statistically significant difference between the control
group and the MIS and ST groups according to age.
Follow-up
Follow-up was scheduled at 4 months postoperatively
and then annually; the tests were repeated as before.
Among the MIS group of 24 patients, 5 were not
investigated with psychometry and EEG and 2 patients
could not be completely investigated during follow-up.
Among the ST group of 21 patients, 1 was not inves-
tigated and 2 were not completely investigated.
Due to several administrative and other factors there
were considerable variations in the time between
operation and the first and second follow-up. The
median postoperative interval until the first follow-up
was 7.4 months (range 2.5–15), and until the second
follow-up 14.7 months (range 10–26.7). Further
follow-up could not be statistically analysed.
Data management
There were data losses in EEG and neuropsychological
tests. For example, preoperative EEG data were
available in 18 patients later treated with MIS and in 6
patients later treated with ST. At the first follow-up
there were 17 MIS patients and 7 ST patients with
EEG data, and at the second follow-up 16 MIS and 7
ST patients with EEG. Complete EEG data on every
occasion were obtained in 12 MIS patients and
2 ST patients. As another example, results from the
psychological test ‘Synonyms’ were available before
treatment in 18 MIS and 18 ST patients, at first
follow-up in 17 MIS and 13 ST patients and at second
follow-up in 15 and 13 patients. Complete results from
the Synonyms were obtained for 14 MIS patients and
10 ST patients. Complete data from all tests on all
three occasions were available for 6 MIS and 2 ST
patients.
To achieve a sufficient number of similar subjects
with complete observations for statistical analysis tests,
the scores from the first and second follow-ups were
averaged. If only one observation was available this
score was used instead of the average. The new vari-
ables created in this way are called ‘postoperative’
thereafter.
The numbers of patients with complete neuro-
psychological preoperative and postoperative test
results were eight for the MIS group and seven for the
ST group. These sample sizes were considered inade-
quate to be representative of the whole groups. Thus, a
‘core material’ was derived comprising those tests with
the highest number of common patients with complete
preoperative and postoperative test results. A maxi-
mum of four missing observations within a test was
allowed. The core material defined in this way consis-
ted of 16 MIS and 16 ST patients with results from a
Table I. Psychometric tests
Test Reference Measures Good performance
Synonyms 15 Verbal ability High score
Figure Classification 15 Logic inductive ability High score
Test Non-verbal reasoning functioning
Block Design Test 16 Visual spatial capacity High score
Memory for Design Test 17 Memory functioning Low score
Revised Visual Retention Test 18 Memory functioning Low score
Paired Associates Test 19 Memory functioning High score
Digit Symbol Test 16 Perceptual ability High score
Dot Test 20 Perceptual ability Low score
Trial Making Test (TMT) 21 Perceptual ability Low score
Colour Word Test (CWT) 22 Intellectual flexibility Low score
Cylinder Board Test (Cyl) 23 Psychomotor capacity High score
Reaction Time Psychomotor capacity Low score
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core of 14 neuropsychological tests preoperatively and
as averages of first and second follow-ups (or estimates
from one of them) postoperatively.
There were 5 women of median age 51.4 years
(range 46.4–56.4) and 11 men of median age 50.9
(range 40–61.8) in the MIS group. In the ST group
there were 6 women of median age 43.7 years (range
33.4–54) and 10 men of median age 56.8 (range
48.5–64.9). There was no statistical difference in age
or gender distribution between the core material and
the other patients (core material: n=32, median age
51.5 years, range 41.5–61.5; other patients: n=13,
median age 54.0 years, range 43.3–64.7; df=43;
t=0.75; p=0.46), (core material: 11 women, 21 men;
other patients: 3 women and 10 men; df=1; df=1;
w2=0.15; p=0.70).
Statistics
Non-parametric statistical methods were applied as far
as possible. Fisher’s exact probability test and the
Mann–Whitney U-test were used for testing differ-
ences between the treatment groups regarding data on
the nominal and ordinal scale levels, respectively.
Analysis of variance, repeated measures, was applied
in testing differences between the two treatment
groups over time. The statistical computations were
performed by the computer program Statview (Abacus
Concepts Inc., Berkely, CA, USA). The rejection limit
for the null-hypothesis was set to 0.5. All tests were
two-tailed.
Results
No patient died during follow-up. Median follow-up
was 14.7 months, range 5 days–8 years.
Blood tests
There were no statistically significant differences
between the MIS and the ST groups during follow-up.
Anti-encephalopathic drugs
About half the patients in each treatment group
received drugs with a known effect on the develop-
ment of encephalopathy. There was no systematic
treatment with lactulose and/or paromomycin, and the
treatment was evenly spread in the two treatment
groups, except at first follow-up in the sclerotherapy
group, in whom more drugs were administered.
Recurrent bleeding
During follow-up there was one patient in the MIS
group who had to be transfused with 1–3 units of blood
at first and second follow-up (median 14.7 months). In
the ST group three patients were transfused up to the
first follow-up with 1–3 units, three patients with 4–6
units and two patients with 7–9 units. Up to the second
follow-up two patients were transfused with 4–6 units,
one patient had 7–9 units and three patients received
410 units of blood. The differences at the first and the
second follow-up were statistically significant (Fisher’s
exact test, p=0.0073 and 0.039, respectively).
Hospitalisation because of overt HE
Two patients in the MIS group developed overt HE
and were hospitalised for treatment. One patient had a
period of heavy alcohol intake 2 years postoperatively
and developed liver coma. After treatment with lac-
tulose he recovered. The other patient was taken to
hospital 3 years postoperatively with signs of encepha-
lopathy, he also suffered from a psychiatric disorder
and was found to have an excessive concentration of
lithium in the blood, besides liver insufficiency. He too
recovered after lactulose treatment.
Neuropsychological findings
Only 3 of 13 patients in the rest of the original material
had preoperative neuropsychological test results, so no
meaningful statistical calculations could be performed
between the core material and the rest of the material.
There was no significant difference in any neuro-
psychological test score between the MIS and ST
groups using the Mann–Whitney U-test in the core
material.
Significant changes between preoperative and post-
operative results were found (according to ANOVA,
repeated measures), for the Synonyms, Block Design
Test, Memory for Design Test-error scores and the
Digit Symbol test (Table I). Significant interactions
between groups and order of occasions were found in
the tests Synonyms, Memory for Design Test, error
scores, Revised Visual Retention Test, correct answers
and error scores and Digit Symbol (Table I).
According to the classification guidelines proposed
by Guilford [24], 62 of a possible maximum of 105
correlation coefficients (rho) between the core neuro-
psychological tests before operation were moderate or
high.
The differences in performance were most
pronounced in tests assessing visuo-spatial memory
ability, the Revised Visual Retention Test and the
Memory for Design Test. In a previous investigation,
these particular tests differentiated well between
patients with mild dementia caused by chronic toxic
encephalopathy due to organic solvents, and patients
with moderate-severe dementia caused by cerebro-
vascular diseases or presenile dementia of Alzheimer’s
type [25]. The results from the preoperative testing
thus indicate that the ST patients had more pro-
nounced HE than the MIS patients.
At the 12-month follow-up psychometric testing,
however, the MIS patients performed statistically
worse than the ST patients in 3 of the 15 test variables:
Synonyms, Block Design Test and Colour Word Test
(Table II). The p value for follow-up was also statisti-
cally significant, at 0.030 (Table II). Furthermore, the
MIS patients performed worse than the ST patients in
68 B. Isaksson et al.
Table II. ANOVA (repeated measures) of neuropsychological test results preoperatively (Pre) and postoperatively (Post) in the core material
between the MIS and ST groups
df F p Group M+SD Pre M+SD Post n
Synonyms
A Group 1,30 0.00 0.96 MIS 19.8+5.4 20.1+4.9 16
B Order 1,30 7.87 0.009** ST 18.9+7.7 20.8+7.0 16
AB 1,30 4.60 0.04*
Figure Classification
A Group 1,30 0.21 0.65 MIS 18.4+4.4 17.6+4.6 16
B Order 1,30 0.04 0.85 ST 16.7+5.5 17.8+5.5 16
AB 1,30 2.05 0.16
Block Design Test
A Group 1,28 0.09 0.77 MIS 19.6+6.5 20.4+6.6 16
B Order 1,28 4.56 0.042* ST 18.2+6.8 20.3+7.3 14
AB 1,28 0.90 0.35
Memory for Design Test, Error Scores
A Group 1,27 0.41 0.53 MIS 4.71+4.5 4.71+4.5 14
B Order 1,27 4.94 0.035* ST 6.87+5.0 4.73+4.9 15
AB 1,27 4.94 0.035*
Revised Visual Retention Test, Correct Answers
A Group 1,30 0.24 0.62 MIS 6.13+2.1 5.50+1.6 16
B Order 1,30 0.10 0.75 ST 5.13+1.5 5.94+1.9 16
AB 1,30 5.89 0.021*
Revised Visual Retention Test, Error Answers
A Group 1,29 0.08 0.78 MIS 6.00+4.4 7.13+3.5 15
B Order 1,29 0.09 0.77 ST 6.94+3.5 5.50+3.4 16
AB 1,29 6.38 0.017*
Paired Associates, Correct Answers
A Group 1,30 0.10 0.76 MIS 20.4+4.7 20.5+4.0 16
B Order 1,30 0.35 0.56 ST 20.6+5.4 21.3+4.6 16
AB 1,30 0.28 0.60
Digit Symbol
A Group 1,30 0.23 0.64 MIS 34.1+11.8 34.8+10.1 16
B Order 1,30 8.29 0.0073** ST 34.0+12.4 39.1+15.4 16
AB 1,30 4.70 0.038*
Dot Test, Time
A Group 1,30 0.01 0.92 MIS 486+113 477+104 16
B Order 1,30 0.91 0.35 ST 495+103 476+145 16
AB 1,30 0.11 0.74
Dot Test, Errors
A Group 1,29 0.02 0.90 MIS 14.5+11.6 12.9+8.0 15
B Order 1,29 0.65 0.43 ST 14.7+11.8 13.7+9.0 16
AB 1,29 0.03 0.86
Colour Word Test, Time
A Group 1,29 0.01 0.93 MIS 145+50 150+49 15
B Order 1,29 0.05 0.83 ST 151+64 148+73 16
AB 1,29 0.78 0.38
Cylinder Board, Right Hand
A Group 1,30 1.05 0.31 MIS 70.7+10.7 68.3+9.5 16
B Order 1,30 0.19 0.66 ST 63.8+16.9 65.3+17.2 16
AB 1,30 3.04 0.09
Cylinder Board, Left Hand
A Group 1,26 0.03 0.87 MIS 63.4+9.6 62.4+8.9 14
B Order 1,26 0.00 0.98 ST 61.8+12.0 62.7+12.7 14
AB 1,26 0.66 0.43
Cylinder Board, Difference
A Group 1,26 0.01 0.93 MIS 6.29+5.2 5.00+3.6 14
B Order 1,26 1.13 0.30 ST 5.57+3.7 5.46+3.6 14
AB 1,26 0.81 0.38
Reaction Time, Median
A Group 1,29 0.67 0.42 MIS 1.60+0.74 1.73+0.86 15
B Order 1,29 1.11 0.74 ST 1.94+0.93 1.88+0.92 16
AB 1,29 0.85 0.37
* p50.05.
** p50.01.
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an additional 10 test variables, although these differ-
ences were not statistically significant (e.g. in the
Memory for Design Test).
To study the effects of the two different treatment
methods, MIS and ST, we considered it important to
evaluate patterns in psychometric test performances
rather than performance in single tests. The general
pattern of the test performance for ST patients was an
improvement after treatment as opposed to the MIS
patients’ test performance, which deteriorated over
time.
EEG findings
The preoperative LFP median was 46 (SD 62) for the
MIS group (n=17), median 47 (SD 49) for the ST
group (n=5) and median 41 (SD 53) for the control
group (n=26). The postoperative medians were 58
(SD 69) for the MIS group (n=17) and median 37
(SD 35) for the ST group (n=5) (Table III).
HE in relation to portal flow
The preoperative evaluation of the 20 MIS patients
showed hepatopetal flow in 16 (80%), hepatofugal flow
in 2 (10%) and mixed flow in 2 (10%) patients. During
first follow-up only three patients (16%) had preserved
hepatopetal flow, in (84%) had the flow nine changed
to hepatofugal. At the second follow-up, at 12 months,
three patients (30%) had hepatopetal flow and seven
(70%) had hepatofugal flow.
Discussion
Factors known to influence HE are the aetiology of
cirrhosis, intake of alcoholic beverages, age over 60
years (as older patients are at greater risk of devel-
oping encephalopathy) and low serum albumin levels
[6,11,26]. There were no significant differences be-
tween the two treatment groups in these aspects and
no differences in liver function parameters between the
MIS and the ST groups. Gitlin and associates reported
elevations in liver parameters in their group of cirrhotic
patients, but they could not find any correlation
between biochemical and psychological tests [27].
Warren and his group [28,29] stressed the impor-
tance of hepatic portal perfusion in preventing post-
operative HE; later studies [30–32] supported this
hypothesis. Our findings are in agreement: portal flow
did influence the development of HE.
The use of anti-encephalopathic drugs was evenly
distributed in the two groups, except at the first follow-
up time when the sclerotherapy patients received more
drugs. This variable does not seem to influence the
trend in deterioration of the three psychometric tests,
as the ST group did better at both follow-up times.
Rypins and colleagues [33] used a 10-mm portacaval
shunt in their study. They could not find any support
for the concept that portal pressure is important in the
development of postoperative HE but rather the portal
flow. In a later study from the same authors [32]
comparing 8-mm grafts to 16-mm portacaval H grafts,
hepatopetal flow was maintained in the 8-mm graft
group during follow-up, which was not the case in the
16-mm group. They also found significantly greater
encephalopathy-free survival for the smaller diameter
graft group. Rikkers and co-workers obtained similar
findings [3] when distal splenorenal shunt was
compared with sclerotherapy; although hepatic portal
perfusion was better after ST there was no major
difference between the groups in terms of post-therapy
psychoneurological function.
In both the MIS and the ST group we found a high
incidence of preoperative encephalopathy. However,
the results from the preoperative psychometric testing
showed that the ST patients had more pronounced
HE than the MIS patients at the onset of the study.
The differences in test performances were more
pronounced in tests previously known to differentiate
well between mild and moderate-severe dementia.
Using unbalanced repeated measurement of variance,
we found that during follow-up the patients in the
shunt group performed significantly worse in seven
tests, which measure either verbal ability (Synonyms),
visuo-spatial ability (Block Design Test and Revised
Table III. ANOVA (repeated measures) of EEG and Trail Making Test results in available patients with preoperative and postoperative
results in the MIS and ST groups
df F p Group M+SD before M+SD after n
EEG
A Group 1,20 1.02 0.32 MIS 48.8+17.5 59.4+19.3 17
B Order 1,20 1.00 0.33 ST 46.4+21.6 45.4+15.3 5
AB 1,20 1.46 0.24
Trail Making Test A
A Group 1,22 0.54 0.47 MIS 56.6+16.9 58.6+23.0 13
B Order 1,22 0.19 0.67 ST 66.5+28.5 61.1+22.6 11
AB 1,22 0.86 0.36
Trail Making Test B
A Group 1,22 1.03 0.32 MIS 80.3+21.7 93.1+34.9 13
B Order 1,22 0.04 0.84 ST 114.7+77.2 103.9+74.7 11
AB 1,22 6.16 0.021*
* p50.05.
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Visual Retention Test Correct/Error Answers),
memory function (Memory for Design Test, Error
Score), perceptual ability (Digit Symbol Test), cogni-
tive motor abilities (Trial Making Test B) or intellec-
tual flexibility (Colour Word Test). The other tests that
evaluate reasoning function, memory function and
psychomotor capacity showed no significant difference
between the two treatment groups.
EEG with spectral analysis showed no significant
difference between groups at follow-up. To evaluate
hepatic encephalopathy in this group of patients at risk
of developing encephalopathy, psychometric tests
sensitive to diffuse global cognitive dysfunction should
be used. Other studies that have evaluated encepha-
lopathy after a distal splenorenal shunt (which acts
as a selective shunt) [5] and TIPS (which acts as a
total shunt) [7] have shown a somewhat more
pronounced encephalopathy after shunting than after
sclerotherapy.
In our study we used a 14-mm mesocaval inter-
position shunt as the surgical alternative to sclero-
therapy. This shunt is a total shunt, as we found that
almost all patients had hepatofugal portal flow after 12
months. Our findings are in line with the previously
cited works: test performance in MIS patients dete-
riorated over time compared with that in ST patients,
whose test performance improved over time. Using an
MIS of smaller diameter (10 or 12 mm), Paquet and
colleagues found that hepatopetal flow was preserved
during a follow-up of about 4 years, with no case of
chronic HE and 510% of acute HE [34].
Gitlin and associates [35] reported a 70% incidence
of subclinical HE in a study of non-shunted and well
compensated cirrhotic patients. They found three
psychometric tests that could identify subclinical HE:
the Digit Symbol Test, the Block Design Test and the
Trailmaking Test. Srivastava and colleagues found a
66% incidence of subclinical HE in patients with
cirrhosis and portal-systemic shunting, although there
was no major impairment in fitness to drive [36].
According to Van der Rijt and associates [37], all
known electrophysiological methods are non-specific
for latent HE and no method is superior to EEG with
spectral analysis.
In our previous analysis of this study with regard
to rebleeding and surgical complication [9], the
encephalopathy was assessed by psychometric tests
and EEG analysis. Patients were scored and divided
into three groups in a similar way to many other reports
[3, 34]. In this analysis no difference could be observed
in the encephalopathy rate between the two treatment
arms. However, to evaluate shunting procedures as
carefully as possible, we considered it important to
perform a detailed analysis of all the test results. It
became apparent that the shunted patients fared worse
than the patients undergoing sclerotherapy.
In conclusion, in this prospective randomised study
we found that patients treated with mesocaval inter-
position shunt show a progressive general reduction in
intellectual capacity, which is not clinically evident but
can be detected on psychometric testing, as opposed to
patients treated with sclerotherapy, who show general
intellectual improvement. The importance of these
observations in relation to the development of clinically
overt encephalopathy is not fully understood at the
present time. We believe that it is important to make a
detailed analysis of subclinical encephalopathy, eval-
uating shunting procedures in patients with portal
hypertension and bleeding oesophageal varices.
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